# V1 Empirics Check — x-ai/grok-4.1-fast (Variant B)

**Model:** x-ai/grok-4.1-fast
**Variant:** B
**Date:** 2026-03-13T10:06:07.225482

---

### 1. Idea Fidelity
The paper largely pursues the original idea manifest, using staggered adoption of state drug price transparency laws (2016-2024, 21 states) and NADAC data to test for strategic threshold avoidance via bunching on price increases. It exploits cross-threshold variation (e.g., 10% vs. 16%) and staggered timing, as proposed, and confirms data access and sample size feasibility (~888k brand drug-week obs collapsed to ~27k semi-annual changes). However, it diverges in key ways: (i) it uses semi-annual (not annual or weekly) price changes, creating a mismatch with annual policy thresholds; (ii) it finds no bunching/avoidance but instead tail compression, flipping the expected mechanism; and (iii) it omits the proposed CS-DiD for dynamic effects, relying instead on pre-post bunching, simple dose-response, and placebos. These shifts weaken fidelity to the "strategic threshold avoidance" research question but adapt coherently to the data.

### 2. Summary
This paper examines whether staggered state drug price transparency laws (2016-2024) restrained brand-name pharmaceutical price increases, using semi-annual NADAC changes for ~6,200 drugs (2013-2025). It documents a collapse in the share of semi-annual increases exceeding 10% (from 25% pre-2018 to <1% post), attributing this to tail compression rather than threshold bunching, with a dose-response to the number of active states. Identification relies on bunching estimators, threshold shifts (10% vs. 16%), and placebos, suggesting transparency deters via reputational/political costs rather than narrow avoidance.

### 3. Essential Points
The paper has potential but requires major revisions to support causal claims. Three critical issues must be addressed:

1. **Mismatch between policy thresholds and outcome frequency**: Laws specify *annual* thresholds (e.g., Oregon's 10% annual), but the analysis uses *semi-annual* changes exceeding 10% per half-year (~21% annualized). This inflates pre-period shares (>10% semi-annual = 25%, plausible for large hikes) and misaligns bunching windows with policy kinks. Recompute outcomes as annual changes (last H2 price to next H2, or year-over-year) to match institutions; semi-annual may proxy but risks confounding with intra-year dynamics.

2. **Unreliable bunching estimates due to sparse post-data**: Post-2018, observed counts near 10% are low (e.g., 1,039 in ±2pp window), yielding implausible negative counterfactuals (e.g., -654) and huge SEs (4.4). Negative excess mass ($\hat{b}<-2$) post contradicts smooth-density null and suggests empty bins, biasing against bunching. Pool post-periods or use finer pre-data for counterfactuals; report bin-level counts/plots (essential for bunching papers); bootstrap more replications (e.g., 1,000+). If sparsity persists, downgrade to simple DiD.

3. **Weak causal identification amid confounders**: No drug or staggered DiD (promised in manifest); dose-response is OLS on time-invariant $N_t^{laws}$ without FE/controls, capturing any post-2017 trend (e.g., IRA 2022, biosimilars). 2017 (CA-only) is ambiguous (pre- or post-?). Implement CS-DiD (e.g., Sun/Callaway) treating state-adoptions as shocks, weighting by state drug shares (via SDUD data, per manifest); add event studies. Placebo thresholds help but show systematic $\Delta\hat{b}<0$ at several (7-15%), undermining specificity.

Failure to fix these risks rejection, as conclusions overclaim causality.

### 4. Suggestions
**Data and Sample Enhancements (20% weight)**: Align fully with manifest—use weekly NADAC for annual % changes ((P_{t+52}-P_t)/P_t) on ~888k brand-weeks, trimming extremes consistently. Clarify 2017 treatment (CA 16% binding?); extend pre-period to 2013H1. Weight obs by market share (SDUD data, logged in manifest) to prioritize high-stakes drugs. Split brands by therapeutic class (e.g., exclude generics-prone like insulins). Report NDC entry/exit rates; test composition bias via balanced panel.

**Figures and Visualization (15% weight)**: Add 2-3 density plots (Kleven-style): (i) full pre/post histograms (0-30%, 0.5pp bins) showing tail compression; (ii) zoomed ±5pp around 10%/16% with polynomial fits; (iii) event-study densities post each adoption (e.g., OR 2018). Yearly evolutions (like Table 3 but graphical) would clarify 2018 shift. Appendix: bin counts, residuals.

**Empirical Strategy Refinements (25% weight)**: Prioritize CS-DiD: $Y_{it} = \sum_k \beta_k g_{t-k} + \alpha_i + \gamma_t + \epsilon_{it}$, where $g_{t-k}$ are leads/lags of state-adoptions, never-treated drugs as control (non-covered brands?). Interact with base-price (for exposure). For bunching, test multiple thresholds dynamically (e.g., 10% post-OR, 16% in 2017-only). Dose-response: add drug FE, period FE, $N_t \times$ price-level. Placebo on generics or OTCs. Quantify economic magnitude: aggregate savings ($ \sum \Delta P \times Q$, via SDUD volumes).

**Mechanism and Heterogeneity Tests (15% weight)**: Formalize "spotlight" vs. avoidance: regress tail moments (90th percentile $\Delta P$, variance above 5%) on treatments. Test substitution (manifest): share of launch-price hikes (Vermont/NV effect?). Heterogeneity: by manufacturer portfolio size (multi-state exposure), HHI (competition), or scrutiny (prior scandals like EpiPen). Fake-threshold RD (Bertanha et al.) for policy endogeneity.

**Robustness and Interpretation (15% weight)**: Event studies around adoptions (not just pre/post). Parallel trends test on mean $\Delta P$ or sub-5% tail. Confounders: control for biosimilar entries (FDA Orange Book), PBM rebates (if proxied), CPI pharma. Appendix: IV for $N_t$ (instrument by state ideology?). Tone down claims—e.g., "associated with" not "caused"; quantify vs. confounds (e.g., IRA explains X%?). SDE table good; extend to bunching $\Delta\hat{b}$.

**Writing and AER:Insights Fit (10% weight)**: Trim to 15 pages (current ~20 LaTeX); move appendices. Intro: hook with Humira example (manifest). Abstract: specify semi-annual caveat. JEL/keywords fine. Add theory section (2pp) modeling spotlight (e.g., political cost $c \cdot \Pr(>threshold)$). Citations: add Kleven 2016 properly; recent transparency lit (e.g., Dafny et al.). Strong contribution potential if ID strengthened—first distributional evidence on pharma transparency, novel mechanism.
